Comparison of various doses of oral cannabidiol for treating refractory epilepsy indications: a network meta-analysis.

ABSTRACT:

Aim

To evaluate the comparative efficacy and safety of various doses of oral cannabidiol (CBD) in treating refractory epilepsy indications, thus providing more informative evidence for clinical decision-making.

Methods

A literature search of PubMed, Embase, the Cochrane library, and Web of Science (WoS) was performed to retrieve relevant randomized controlled trials (RCTs) that compared different doses of oral CBD with placebo or each other in refractory epilepsy indications. The search was limited from the inception of each database to January 3, 2023. Relative risk [RR] with a 95% confidence interval [CI] was used to express results. STATA/SE 14 was employed for network meta-analysis.

Results

Six RCTs involving 972 patients were included in the final data analysis.

SUBMITTER: Wang X 

PROVIDER: S-EPMC11238246 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature